Marie Thibault
Stock Analyst at BTIG
(3.90)
# 678
Out of 4,711 analysts
74
Total ratings
54.29%
Success rate
9.23%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EMBC Embecta | Upgrades: Buy | $26 | $20.23 | +28.52% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $266.57 | +1.29% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $169.52 | +0.28% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $40.01 | +62.46% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $88.95 | +4.55% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $75.44 | +48.46% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $30.72 | +72.53% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $80.04 | +49.93% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.40 | - | 2 | Jun 25, 2024 | |
| VERO Venus Concept | Downgrades: Neutral | n/a | $0.32 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $11.01 | +81.65% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $90.39 | +54.88% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.83 | +63.93% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $114.23 | +9.43% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $97 | $55.45 | +74.93% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.85 | +278.38% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.39 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.46 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $216.65 | -97.23% | 1 | Apr 9, 2020 |
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $20.23
Upside: +28.52%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $266.57
Upside: +1.29%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $169.52
Upside: +0.28%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $40.01
Upside: +62.46%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $88.95
Upside: +4.55%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $75.44
Upside: +48.46%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $30.72
Upside: +72.53%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $80.04
Upside: +49.93%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.40
Upside: -
Venus Concept
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $11.01
Upside: +81.65%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $90.39
Upside: +54.88%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $1.83
Upside: +63.93%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $114.23
Upside: +9.43%
Oct 17, 2022
Maintains: Buy
Price Target: $100 → $97
Current: $55.45
Upside: +74.93%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.85
Upside: +278.38%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.39
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.46
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $216.65
Upside: -97.23%